Company Overview - Sagimet is a clinical stage biopharmaceutical company focused on developing programs that inhibit fatty acid synthase (FASN) [2] - FASN is an enzyme that regulates various organs and pathways in the body, and its overexpression is linked to several health issues [2] Key Development Areas - The primary development focus is on MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease), acne, and certain solid tumors in oncology that require FASN for disease progression [2] - Significant work has been conducted in MASH and acne, with preclinical and clinical studies demonstrating the effectiveness of the lead molecule, denifanstat [3]